^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG CLASS:
Steroid receptor agonist
DRUG CLASS:
Steroid receptor agonist
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
3d
LASER-LICH1: Laser vs Clobetasol for Lichen Sclerosus (clinicaltrials.gov)
P3, N=198, Recruiting, Ruhr University of Bochum | Trial completion date: Nov 2023 --> Oct 2024 | Trial primary completion date: Jul 2023 --> Jun 2024
Trial completion date • Trial primary completion date
5d
KETOPAIN: Non-steroidal Anti-inflammatory in Cardiac Surgery (clinicaltrials.gov)
P=N/A, N=238, Recruiting, Centre Hospitalier Universitaire, Amiens
New trial • Surgery
|
dexamethasone injection
7d
Steroids After Spine Fusion Surgery (clinicaltrials.gov)
P4, N=420, Not yet recruiting, Oregon Health and Science University | Trial completion date: Oct 2023 --> Oct 2026 | Trial primary completion date: Oct 2023 --> Oct 2026
Trial completion date • Trial primary completion date • Surgery
12d
ALL Adult Consortium Trial: Adult ALL Trial (clinicaltrials.gov)
P2, N=112, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date
|
imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine
13d
Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis (clinicaltrials.gov)
P2, N=33, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Apr 2024 | Trial primary completion date: Jul 2025 --> Apr 2024
Trial completion • Trial completion date • Trial primary completion date
|
prednisone • nintedanib
13d
Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis (clinicaltrials.gov)
P4, N=50, Completed, Psoriasis Treatment Center of Central New Jersey | Unknown status --> Completed
Trial completion
14d
Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD (clinicaltrials.gov)
P4, N=118, Not yet recruiting, Peking University People's Hospital
New P4 trial
|
prednisone
14d
Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis (clinicaltrials.gov)
P2/3, N=60, Recruiting, Peking University International Hospital | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Jul 2025 --> Dec 2025
Trial completion date • Trial primary completion date
|
CRP (C-reactive protein)
|
prednisone • sirolimus
17d
PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov)
P3, N=105, Recruiting, AstraZeneca | Trial completion date: Apr 2024 --> Nov 2024 | Trial primary completion date: Apr 2024 --> Nov 2024
Trial completion date • Trial primary completion date
19d
Effectiveness of Cervical Transforaminal Epidural Steroid Injection (clinicaltrials.gov)
P4, N=33, Completed, University of Utah | Active, not recruiting --> Completed
Trial completion
|
dexamethasone injection
19d
Dose of Corticosteroids in COPD (clinicaltrials.gov)
P4, N=89, Terminated, Rutgers, The State University of New Jersey | Suspended --> Terminated; Lack of research staff to recruit participants
Trial termination
|
prednisone • methylprednisolone sodium succinate
19d
One Year Trial Evaluating Safety of Ozurdex With Eylea (clinicaltrials.gov)
P4, N=50, Completed, Texas Retina Associates | Unknown status --> Completed
Trial completion
|
Eylea (aflibercept intravitreal)
23d
EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells. (PubMed, Cell Mol Life Sci)
Similarly, GR's regulated transcriptome and receptor binding were hindered, not linked to reduced GR expression but to diminished FOXA1 chromatin binding, restricting GR signaling. Overall, our findings highlight how EP300/CREBBP inhibition distinctively curtails oncogenic transcription factors' signaling, suggesting the potential of coregulatory-targeted therapies in PCa.
Journal
|
AR (Androgen receptor) • CREBBP (CREB binding protein) • EP300 (E1A binding protein p300) • FOXA1 (Forkhead Box A1) • NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1)
24d
OM: Ozurdex Monotherapy Trial (clinicaltrials.gov)
P4, N=84, Recruiting, Ottawa Hospital Research Institute | Trial completion date: Feb 2025 --> Sep 2027 | Trial primary completion date: Feb 2025 --> Sep 2027
Trial completion date • Trial primary completion date
|
prednisone
24d
High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors (clinicaltrials.gov)
P1/2, N=35, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting | N=15 --> 35
Enrollment open • Enrollment change
|
methylprednisolone sodium succinate
25d
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2) (clinicaltrials.gov)
P3, N=0, Withdrawn, EyePoint Pharmaceuticals, Inc. | Trial completion date: Apr 2024 --> Sep 2023 | Trial primary completion date: Apr 2024 --> Sep 2023
Trial completion date • Trial primary completion date • Surgery
25d
OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED) (clinicaltrials.gov)
P2, N=100, Active, not recruiting, Ocular Therapeutix, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Feb 2024 --> May 2024
Enrollment closed • Trial completion date
26d
PIPE: Prednisone in Cystic Fibrosis Pulmonary Exacerbations (clinicaltrials.gov)
P3, N=76, Completed, The Hospital for Sick Children | Recruiting --> Completed | Trial completion date: May 2023 --> Oct 2023 | Trial primary completion date: May 2023 --> Oct 2023
Trial completion • Trial completion date • Trial primary completion date
|
prednisone
26d
A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis (clinicaltrials.gov)
P3, N=604, Completed, LEO Pharma | Active, not recruiting --> Completed
Trial completion
28d
TNF Superfamily and ILC2 Activation in Asthma. (PubMed, Biomolecules)
ILC2 numbers are increased in the airways of asthmatics and with the greatest numbers of activated ILC2 detected in sputa from severe prednisone-dependent asthma with uncontrolled eosinophilia...The tumor necrosis factor super family (TNFSF) and its receptors (TNFRSF) promote ILC2 activity. In this review, we discuss evidence supporting a relationship between ILC2 and TNFSF/TNFRSF axis in eosinophilic asthma and the role of this relationship in severe asthma with airway autoimmune responses.
Review • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL13 (Interleukin 13) • IL5 (Interleukin 5)
1m
The multifaceted therapeutic value of targeting steroid receptor coactivator-1 in tumorigenesis. (PubMed, Cell Biosci)
In addition, the antitumour effect of pharmacological inhibition of SRC-1 with agents including various small molecules or naturally active compounds has been reported, but their practical application in clinical cancer therapy is very limited. For this review, we gathered typical evidence on the oncogenic role of SRC-1, highlighted its major collaborators and regulatory genes, and mapped the potential mechanisms by which SRC-1 promotes primary tumour progression.
Review • Journal
|
NCOA1 (Nuclear Receptor Coactivator 1)
1m
Particulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection (clinicaltrials.gov)
P4, N=230, Recruiting, University of New Mexico | Not yet recruiting --> Recruiting
Enrollment open
|
dexamethasone • methylprednisolone acetate
1m
IMPROVE-MC: Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy. (clinicaltrials.gov)
P4, N=100, Recruiting, Medical University of Warsaw | Not yet recruiting --> Recruiting | Trial completion date: Sep 2026 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Sep 2027
Enrollment open • Trial completion date • Trial primary completion date • Biopsy
|
prednisone
1m
FORCE2: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid (clinicaltrials.gov)
P3, N=580, Active, not recruiting, Chiesi Farmaceutici S.p.A. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Jun 2024 | Trial primary completion date: Oct 2023 --> Jun 2024
Enrollment closed • Trial completion date • Trial primary completion date • Head-to-Head
1m
OCT and OCT-Angiography Biomarkers of Treatment Response to Dexamethasone Implant in Macular Edema Due to Retinal Vascular Diseases - DME and RVO (clinicaltrials.gov)
P=N/A, N=50, Recruiting, IRCCS Multimedica
New trial
1m
Treatment Of Oral Lichen Planus (clinicaltrials.gov)
P=N/A, N=15, Recruiting, Mansoura University
New trial
1m
Steroid receptor coactivator 1 promotes human hepatocellular carcinoma invasiveness through enhancing MMP-9. (PubMed, J Cell Mol Med)
Treatment with Bufalin, known to inhibit SRC-1 expression, significantly decreased MMP-9 expression and inhibited HCC metastasis in both in vitro and in vivo settings. Our results demonstrated the pivotal role of SRC-1 as a critical modulator in HCC metastasis, presenting a potential therapeutic target for HCC intervention.
Journal
|
MMP9 (Matrix metallopeptidase 9)
1m
Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (clinicaltrials.gov)
P4, N=0, Withdrawn, Wake Forest University Health Sciences | N=150 --> 0 | Suspended --> Withdrawn
Enrollment change • Trial withdrawal
|
Visudyne (verteporfin) • Lucentis (ranibizumab)
1m
Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) (clinicaltrials.gov)
P3, N=520, Completed, Oxford University Clinical Research Unit, Vietnam | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Apr 2023
Trial completion • Trial completion date
|
dexamethasone injection
1m
A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma (clinicaltrials.gov)
P3, N=2518, Active, not recruiting, Bond Avillion 2 Development LP | Recruiting --> Active, not recruiting
Enrollment closed
2ms
Dexamethasone in Total Knee Arthroplasty (clinicaltrials.gov)
P4, N=429, Recruiting, Rush University Medical Center | Trial primary completion date: Feb 2024 --> May 2024
Trial primary completion date
|
dexamethasone injection
2ms
Rituximab in the First Episode of Paediatric Nephrotic Syndrome (clinicaltrials.gov)
P3, N=138, Not yet recruiting, Children's Hospital of Fudan University | Initiation date: Jan 2024 --> Apr 2024
Trial initiation date • Head-to-Head
|
CD20 positive
2ms
Anti-ulcerative colitis effects of chemically characterized extracts from Calliandra haematocephala in acetic acid-induced ulcerative colitis. (PubMed, Front Chem)
Prednisone at 2 mg/kg dose and plant extracts at 250, 500, and 750 mg/kg doses were given to Wistar rats for 11 days, which were given acetic acid on 8th day through the trans-rectal route for the induction of ulcerative colitis... It was concluded based on study outcomes that methanolic and n-hexane extracts of Calliandra haematocephala exhibited anti-ulcerative colitis activity through modulation of antioxidant defense mechanisms and the immune system. In this context, C. haematocephala can be considered as a potential therapeutic approach for cure of ulcerative colitis after bioassay-directed isolation of bioactive phytochemicals and clinical evaluation.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL4 (Interleukin 4)
|
prednisone
2ms
Treatment of Apomorphine-induced Skin Reactions: a Pilot Study (clinicaltrials.gov)
P2, N=13, Terminated, University Medical Center Groningen | N=20 --> 13 | Unknown status --> Terminated; Delayed inclusion - stopped when 10 patients completed the study
Enrollment change • Trial termination
2ms
Erector Spinae Plane Block Versus Intercostal for VATS (clinicaltrials.gov)
P=N/A, N=100, Completed, McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown status --> Completed
Trial completion • Surgery
|
dexamethasone injection
2ms
ACADIA: Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (clinicaltrials.gov)
P3, N=440, Not yet recruiting, AstraZeneca
New P3 trial
2ms
Genicular Nerve Blocks for Anterior Cruciate Ligament Knee Surgery (clinicaltrials.gov)
P4, N=192, Recruiting, Hospital for Special Surgery, New York | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2024 --> Jan 2025
Trial completion date • Trial primary completion date • Surgery
|
dexamethasone
2ms
Oral Dexamethasone for Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy (clinicaltrials.gov)
P3, N=814, Recruiting, Mansoura University | Not yet recruiting --> Recruiting
Enrollment open
|
dexamethasone injection
2ms
Clinical features and prognostic analysis of checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer (PubMed, Zhonghua Jie He He Hu Xi Za Zhi)
Prednisone≥1 mg·kg-1·d-1 (or equivalent) was the most commonly used initial treatment in CIP patients (50 patients/71.4%)...NSIP pattern and OP pattern were common chest CT manifestations. Complications with pulmonary infections (especially fungal infection or Pneumocystis jirovecii pneumonia), longer duration, longer duration of high-dose corticosteroids were likely potential risk factors for poor prognosis.
Journal • Checkpoint inhibition
|
CRP (C-reactive protein)
2ms
Short-term Oral Steriods for Acute Tinnitus (clinicaltrials.gov)
P=N/A, N=186, Completed, Eye & ENT Hospital of Fudan University | N=129 --> 186
Enrollment change
|
prednisone
2ms
A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis (clinicaltrials.gov)
P3, N=604, Active, not recruiting, LEO Pharma | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Mar 2024 | Trial primary completion date: Jun 2024 --> Feb 2024
Enrollment closed • Trial completion date • Trial primary completion date
2ms
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract (clinicaltrials.gov)
P3, N=65, Completed, Ocular Therapeutix, Inc. | Recruiting --> Completed | Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Dec 2023
Trial completion • Trial completion date • Trial primary completion date • Surgery
Share via
